ADmit Therapeutics

ADmit Therapeutics is a biotechnology company established in 2017 as a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona, Spain. The firm was co-founded by Dr. Marta Barrachina, who serves as CEO, and Jordi Gascón. Dr. Barrachina, a PhD in Biochemistry, began her career at IDIBELL where her research into the brains of deceased Alzheimer's patients led to the discovery of a link between the disease and mitochondrial DNA.

The company is focused on the early prediction of Alzheimer's disease (AD). Its core product is the MAP-AD® test, an in-vitro diagnostic (IVD) tool designed to predict the likelihood of a patient with Mild Cognitive Impairment (MCI) progressing to Alzheimer's dementia. Unlike diagnostic methods that detect existing beta-amyloid or tau proteins, MAP-AD® provides a prognosis, capable of forecasting cognitive decline up to 14 years before dementia manifests. The technology utilizes a blood sample to conduct an epigenetic analysis of mitochondrial DNA methylation signatures. This data is processed by a machine learning algorithm, which also incorporates the patient's age, ApoE genotype, and neuropsychological assessments to generate a risk profile. This approach allows for the identification of at-risk individuals, even those who test negative on PET scans for β-amyloid.

ADmit Therapeutics operates on a dual business model. The primary focus is providing epigenetic services to pharmaceutical companies to optimize patient selection and stratification for clinical trials, thereby accelerating the development of new treatments. The second part of its strategy involves integrating the MAP-AD® test into clinical practice within public and private healthcare systems, making it available to patients through memory units and neurologists once regulatory approvals are secured. The company has received its manufacturing license from the Spanish Agency of Medicines and Medical Devices (AEMPS) and holds ISO 13485 certification. It is pursuing CE marking and FDA approval for commercialization in Europe and the United States.

The company has secured significant funding over several rounds, including investments from Clave Capital, the European Innovation Council (EIC) Fund, the Alzheimer's Drug Discovery Foundation (ADDF), Ship2B, and BStartup Banco Sabadell. In July 2025, the company relocated to new facilities within the Almirall's Innovation Hub “The Hive” in Sant Feliu de Llobregat.

Keywords: Alzheimer's early detection, prognostic blood test, mitochondrial DNA, epigenetics, neurodegenerative diseases, MAP-AD test, Mild Cognitive Impairment, patient stratification, clinical trials, next-generation sequencing, machine learning diagnostics, dementia prediction, precision medicine, biomarker, in-vitro diagnostic, ApoE genotype, personalized medicine, neurobiology, medical diagnostics, biotechnology